Anteris Technologies Global Corp. (AVR)
NASDAQ:AVR
Want to see AVR full AI Analyst Report?
AVR Stock Chart & Stats
$5.68
-$0.12(-2.09%)
At close: 4:00 PM EST
$5.68
-$0.12(-2.09%)
Day’s Range― - ―
52-Week Range$2.85 - $6.95
Previous Close$5.88
Volume157.53K
Average Volume (3M)151.40K
Market Cap
$550.33M
Enterprise Value$198.66M
Total Cash (Recent Filing)$12.58M
Total Debt (Recent Filing)$2.28M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
May 19, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding97,232,056
10 Day Avg. Volume215,658
30 Day Avg. Volume151,395
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-1.27K
Price to Sales (P/S)61.50
P/FCF Ratio-1.48
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue103.85
Enterprise Value/Gross Profit147.82
Enterprise Value/Ebitda-2.15
Forecast
1Y Price Target
$16.00Price Target Upside181.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$8.58M
Bulls Say, Bears Say
Bulls Say
New Long-term Facility Lease With AbatementsA long-term 181k sq ft lease creates a durable operational footprint to scale manufacturing and warehousing for heart valve production. Initial rent abatements materially ease near-term cash outflows while the company ramps facilities, supporting execution of commercialization plans over multiple years.
Sharp Improvement In 2025 Gross Margin (~70%)A materially higher gross margin suggests the underlying product economics or manufacturing efficiency can support profitability as revenue grows. If sustained, this structural margin improvement reduces the revenue threshold needed for operating leverage and longer-term viability of the device business.
Low Absolute Debt Levels Reported In 2025Relatively low nominal debt lessens immediate interest burden and reduces near-term refinancing pressure versus highly leveraged peers. Structurally, lower debt preserves optionality for strategic financing or partnerships to fund commercial scale-up without being constrained by heavy fixed financial charges.
Bears Say
Material Revenue Decline Over TimeSustained revenue deterioration over multiple years signals weak commercial traction for core products and undermines the company’s ability to absorb fixed costs. Over a 2-6 month horizon this structural sales weakness raises the risk that capacity and lease commitments will be underutilized and margins cannot be leveraged.
Consistent, Large Negative Operating And Free Cash FlowPersistent heavy cash burn and a very large 2025 outflow indicate structural dependence on external financing to sustain operations. This constrains strategic flexibility, increases dilution or refinancing risk, and limits the company's ability to fund commercialization or regulatory milestones without capital raises.
Negative Stockholders' Equity (solvency/dilution Risk)Negative equity reflects accumulated losses and weak solvency, reducing access to debt capital on favorable terms and likely forcing dilutive recapitalization if additional funding is needed. This structural balance-sheet weakness elevates financing risk over the medium term.
Anteris Technologies Global Corp. News
AVR FAQ
What was Anteris Technologies Global Corp.’s price range in the past 12 months?
Anteris Technologies Global Corp. lowest stock price was $2.85 and its highest was $6.95 in the past 12 months.
What is Anteris Technologies Global Corp.’s market cap?
Anteris Technologies Global Corp.’s market cap is $550.33M.
When is Anteris Technologies Global Corp.’s upcoming earnings report date?
Anteris Technologies Global Corp.’s upcoming earnings report date is May 19, 2026 which is in 20 days.
How were Anteris Technologies Global Corp.’s earnings last quarter?
Anteris Technologies Global Corp. released its earnings results on Mar 18, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.503 by -$0.237.
Is Anteris Technologies Global Corp. overvalued?
According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued.
Does Anteris Technologies Global Corp. pay dividends?
Anteris Technologies Global Corp. does not currently pay dividends.
What is Anteris Technologies Global Corp.’s EPS estimate?
Anteris Technologies Global Corp.’s EPS estimate is -0.16.
How many shares outstanding does Anteris Technologies Global Corp. have?
Anteris Technologies Global Corp. has 97,232,056 shares outstanding.
What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?
Anteris Technologies Global Corp. reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.503. Following the earnings report the stock price went down -1.34%.
Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?
Currently, no hedge funds are holding shares in AVR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anteris Technologies Global Corp. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (181.69% Upside)
$16.00 (181.69% Upside)
Hedge Fund Trend
Decreased
By 29.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.53%
12-Months-Change
Fundamentals
Return on Equity
-528.38%
Trailing 12-Months
Asset Growth
-69.76%
Trailing 12-Months
Company Description
Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
AVR Stock 12 Month Forecast
Average Price Target
$16.00
▲(181.69% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
Inogen
―
Treace Medical Concepts
―
Rapid Micro Biosystems
―
Ownership Overview
14.01% Insiders
4.52% Mutual Funds
0.56% Other Institutional Investors
76.64% Public Companies and
Individual Investors